Business Context and Reporting Period
Company: Aethlon Medical, Inc. (AEMD.OB)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2008
Business Stage: Development Stage Company
Core Technology: Hemopurifier(R) platform designed to remove viruses and toxins from blood via affinity chromatography and hemodialysis.
Operational Status: The company has not generated revenue from principal operations. It is focused on pre-clinical testing and seeking FDA approval for clinical trials targeting HIV, Hepatitis-C, and biological warfare agents.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2008 | Nine Months Ended Dec 31, 2008 | Balance Sheet (Dec 31, 2008) |
|---|---|---|---|
| Revenues | $0 | $0 | N/A |
| Operating Expenses | $867,369 | $2,223,687 | N/A |
| Net Loss | $(2,344,554) | $(5,156,189) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.12) | N/A |
| Cash and Equivalents | N/A | N/A | $92,020 |
| Total Assets | N/A | N/A | $347,979 |
| Total Liabilities | N/A | N/A | $4,440,625 |
| Working Capital | N/A | N/A | $(4,248,480) |
| Accumulated Deficit | N/A | N/A | $(37,383,445) |
Debt Obligations: Total notes payable (net of discounts) were $352,500, and convertible notes payable (net of discounts) were $2,412,973. Several notes are past due and in default.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the nine months ended Dec 31, 2008, increased to $5.16 million from $3.39 million in the prior year period. This was driven by increased operating expenses and significant non-cash charges.
- Operating Expenses: Increased by approximately 6% year-over-year for the nine-month period, primarily due to a $179,386 increase in payroll and related expenses (largely non-cash stock compensation).
- Debt Restructuring Losses: The company recorded a $1.06 million loss on the extinguishment of debt due to the restructuring of 8% and 9% notes into convertible notes. Additionally, a $607,908 loss was recorded on the settlement of accrued interest and damages.
- Cash Position: Cash decreased from $254,691 at March 31, 2008, to $92,020 at December 31, 2008, a reduction of approximately $162,671.
- Warrant Liability: A change in the fair value of warrant obligations resulted in a non-cash gain of $213,903 for the nine-month period, partially offsetting other expenses.
Guidance, Outlook, Risks, and Unusual Items
Going Concern and Liquidity
Management has raised significant doubt about the company's ability to continue as a going concern. The company has negative working capital of approximately $4.25 million and an accumulated deficit of over $37 million. Current resources are insufficient to fund operations for the fiscal year ending March 31, 2009. The company requires a minimum of $168,000 per month to sustain operations and is actively seeking additional capital through debt or equity financing.
Debt Defaults
The company is in default on various promissory and convertible notes totaling $352,500 in principal. Additionally, the Amended Series A Convertible Notes were in default due to failure to register warrants and make interest payments, though a registration statement was subsequently declared effective in October 2008.
Unusual Items
- Debt Extinguishment: Significant non-cash losses ($1.06 million) recorded due to debt restructuring.
- Stock for Services: Extensive issuance of common stock and warrants to settle accrued expenses, legal fees, and consulting services, resulting in substantial stock-based compensation expenses ($590,832 for the nine months).
Outlook
The company plans to continue R&D on the Hemopurifier(R) platform, specifically targeting "Category A" pathogens. Future capital requirements depend on clinical trial progress and regulatory approvals. No revenue is expected from operations in the foreseeable future.
Investor Verification Checklist
- Liquidity Runway: Verify the status of current capital raising efforts, as cash on hand ($92,020) is insufficient to cover the stated monthly burn rate of $168,000.
- Debt Resolution: Confirm the terms of negotiations with noteholders regarding the $352,500 in past-due notes and the potential for forced conversion or acceleration of debt.
- Regulatory Progress: Monitor the status of the Investigational Device Exemption (IDE) and FDA approval for human clinical trials, which is a prerequisite for any future revenue.
- Dilution Risk: Assess the impact of outstanding warrants, options (14.8 million outstanding), and convertible notes (potential conversion of ~8.6 million shares at floor price) on existing shareholders.
- Related Party Transactions: Review the $598,753 due to related parties and the recent conversions of officer/director debt to equity to understand the extent of related party support and potential conflicts.